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The caspase recruitment domain gene (CARD15) was recently identified as the underlying gene associated with the
IBD1 locus that confers susceptibility to Crohn disease (CD). CARD15 is related to the NOD1/Apaf-1 family of
apoptosis regulators, and three sequence variants (Arg702Trp, Gly908Arg, and Leu1007fsinsC) in the gene were
demonstrated to be associated with CD. We collected a cohort of 231 patients with CD and 71 healthy control
individuals from the Canadian province of Quebec, to determine the prevalence of these sequence variants in an
independent population. Clinical records of all patients were systematically reviewed, and detailed phenotypic
information was obtained. All patient DNA samples were genotyped for the three variants, thus enabling an analysis
of genotype-phenotype correlations. In this cohort, 45.0% of patients with CD carried at least one variant in the
CARD15 gene, compared with 9.0% of control individuals ( ). Allele frequencies of Arg702Trp, Gly908Arg,57P ! 10
and Leu1007fsinsC were 12.9%, 5.2%, and 10.3% in patients with CD, compared with 4.2%, 0.7%, and 0.7%
in control individuals, respectively. Importantly, CARD15 mutants were seen with equal frequency in patients with
familial and sporadic CD. Analysis of the relationship between genotype and phenotype convincingly demonstrates
that CARD15 variants are significantly associated with ileal disease involvement, as opposed to strictly colonic
disease ( ). Moreover, we were able to determine the haplotype structure surrounding this disease gene byP ! .001
genotyping 45 single-nucleotide polymorphisms (SNPs) in a 177-kb region that contained the CARD15 gene. This
structure helps clarify the history of these causal mutations. Finally, this analysis shows that CARD15 involvement
with CD is detectable by use of publicly available SNPs alone.
Introduction
Crohn disease (CD [MIM 266600]) is a chronic, re-
lapsing inflammatory bowel disease (IBD) of unknown
etiology. Estimates of prevalence in the northern half of
the western hemisphere are 40–250/100,000 individuals
in the population (Andres and Friedman 1999). In the
northern hemisphere, a north-south prevalence gradient
exists, with the highest reported rates in Scandinavia and
Canada (Pinchbeck et al. 1988; Ekbom et al. 1991; Bern-
stein et al. 1999). Multiple lines of evidence suggest that
the underlying etiology of IBD is a dysregulated immune
response to microbial organisms in the gastrointestinal
tract and/or a breakdown in the epithelial barrier, which
Received February 25, 2002; accepted for publication April 8, 2002;
electronically published May 17, 2002.
Address for correspondence and reprints: Dr. JohnD.Rioux,Human
Medical and Population Genetics, Whitehead Institute/MIT Center for
Genome Research, One Kendall Square, Building 300,Cambridge,MA
02139-1561. E-mail: rioux@genome.wi.mit.edu
 2002 by The American Society of Human Genetics. All rights reserved.
0002-9297/2002/7101-0009$15.00
leads to inflammatory cell damage. Specifically, this ap-
pears to involve a Th1-predominant (i.e., interleukin-2,
interferon-g, and tumor necrosis factor–a) proinflam-
matory mucosal immune response to the presence of
normal intestinal bacterial flora (Elson 2002; Shanahan
2002). A strong genetic contribution to susceptibility to
CD is supported by a relative risk to siblings of affected
individuals (ls) of 25 (Ahmad et al. 2001) and a con-
cordance rate among MZ twins of ∼40%.
The complexity of the genetic susceptibility in CD is
underscored by the identification, by genomewide scan-
ning, of 110 putative susceptibility regions with sug-
gestive or significant evidence of linkage (Hugot et al.
1996; Satsangi et al. 1996; Cho et al. 1998; Hampe et
al. 1999; Ma et al. 1999; Duerr et al. 2000; Rioux et
al. 2000). The first identified susceptibility locus was
the pericentromeric region on chromosome 16 (IBD1),
which conferred susceptibility to CD only (Hugot et al.
1996). The importance of this locus has been confirmed
by various groups, including the International IBD Ge-
netics Consortium (2001).
The combined strategies of positional cloning and can-
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didate gene analysis recently led two independent teams
to identify the gene that underlies the IBD1 locus (Hugot
et al. 2001; Ogura et al. 2001a). IBD1 encodes the cas-
pase recruitment domain gene protein (CARD15 [pre-
viously known as “NOD2”; MIM 605956]), a mem-
ber of the NOD1/Apaf-1 family of apoptosis regulators
(Inohara et al. 2001; Ogura et al. 2001b). CARD15 is
expressed intracellularly in monocytes andmacrophages,
where it appears to function as a sensor for bacterial
products, such as lipopolysaccharides (LPS), through the
leucine-rich repeat (LRR) domain located in the C-ter-
minal region of the gene. It has been hypothesized that
the sensing of bacterial componentswould, under normal
circumstances, result in the activation of nuclear fac-
tor–kB (NF-kB) and in apoptosis.
Hugot and coworkers (2001) identified a number of
single-nucleotide polymorphisms (SNPs) within the
CARD15 gene and demonstrated that three SNPs, in-
cluding one frameshift mutation (Leu1007fsinsC) and
two missense mutations (Arg702Trp and Gly908Arg),
were associated with CD. To date, functional data are
available only for the frameshift mutation. The presence
of Leu1007fsinsC leads to the truncation of the C-ter-
minal 33 amino acids in the LRR region. An intact LRR
region appears to be necessary for normal bacterial/LPS
recognition, since partial deletion of the LRR, an event
characteristic of the frameshift mutation, was shown to
be associated with hyporesponsiveness to LPS (Ogura
et al. 2001a). This deficit in sensing bacteria would then
result in an exaggerated inflammatory response of the
adaptive immune system; this is supported by the five-
fold increase in NF-kB activation seen in the presence
of the frameshift mutation. Although functional data
are lacking for the other variants, it is tempting to spec-
ulate that these three variants would alter the structure
of the LRR region, resulting in similar abnormalities in
bacterial recognition.
These recent discoveries provide a rational framework
in which to examine genotype-phenotype correlations in
a complex human disease. To this end, we collected a
cohort of 231 well-characterized patients with CD from
the province of Quebec, Canada. Because the prevalence
of the Leu1007fsinsC variant has been examined only in
European and North American populations (Hampe et
al. 2001; Hugot et al. 2001; Ogura et al. 2001a) and
because the Arg702Trp and Gly908Arg variants were
examined exclusively in a European population (Hugot
et al. 2001), the present study provides the first oppor-
tunity to examine the prevalence of all three sequence
variants in an independent population.
In addition, a number of recent reports indicate that
common genetic variation in the human genome exists
as discrete haplotype blocks, each with limited diversity,
separated by intervals of multiple, independent, histor-
ical recombination events (Jeffreys et al. 2000; Daly et
al. 2001). Knowledge of this haplotype structure allows
for common variation in a gene to be tested exhaustively
for association with disease, even if the causal variants
have not been identified (Daly et al. 2001; Goldstein et
al. 2001).
A recent application of the haplotype structure of the
human genome to the study of disease association reveals
that genetic variation in the cytokine gene cluster on chro-
mosome 5q31, a locus known as IBD5 (MIM 606348),
confers susceptibility to CD (Rioux et al. 2001). We
therefore sought to determine the haplotype structure in
a 177-kb region containing the CARD15 gene, and we
discuss the implications of this structure for the history
of the three causal variants.
Subjects and Methods
Patient Characteristics
A cohort of 231 well-characterized patients with CD
from the province of Quebec, Canada, were recruited
(179 from Montreal, 32 from Sherbrooke, 15 from Chi-
coutimi, and 5 from Quebec). All patients were seen by
IBD specialists, and all clinical charts (including the phy-
sicians’ notes, the radiology reports, endoscopy and his-
topathology results, and surgical specimens) were re-
viewed in detail by two investigators (G.W. and S.V.) who
were blinded for the genotype status of each patient. The
patients’ records were systematically reviewed for the fol-
lowing demographic and clinical characteristics: age, sex,
smoking habits, age at diagnosis, disease localization (il-
eal, colonic, or ileocolonic), disease behavior (inflam-
matory, stricturing, or fistulizing), history of abdominal
surgery, presence of extraintestinal clinical manifestations
(e.g., arthritis, uveitis, erythema nodosum), and familial
IBD (Gasche et al. 2000) (table 1). Localization of disease
was defined as the maximal extent of the disease during
the period between diagnosis and latest follow-up. Full
clinical data were obtained for all clinical variables except
for smoking habits, which were incomplete for 29 pa-
tients. Of the total study cohort, the majority of patients,
133 (58%), were of French Canadian origin, and 14%
were of Ashkenazi Jewish origin. The remaining patients
had predominantly European ancestry (19 Italian, 16
English, 12 Sephardic Jewish, 1 Algerian, 4 Armenian, 2
Greek, 1 Haitian, 1 Irish, 3 Polish, 1 Spanish, and 1
Ukrainian).
In a subgroup of 84 patients, both parents were avail-
able, and parental data were collected (i.e., this set of
84 CD trios mostly overlaps with the samples described
as “set D” in our study of the IBD5 locus [Rioux et al.
2001]). A group of 71 healthy individuals served as con-
trols for the 147 patients for whom parental genotypes
were not available. Approval for the study was obtained
from the local institutional review boards, and all par-
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Table 1
Baseline Clinical Characteristics of the Study
Population
Characteristic
No. (%) of
Patients
History of smoking 52 (26.0)
Localization:
Ileitis 68 (29.6)
Colitis 76 (33.2)
Ileocolitis 85 (37.2)
Behavior:
Inflammatory 110 (48.1)
Structuring 42 (18.3)
Fistulizing 77 (33.6)
Previous abdominal surgery 115 (50.2)
Extraintestinal manifestations 94 (41.0)
Familial IBD 78 (34.1)
Age at diagnosis (years):
!20 94 (41.1)
20–40 124 (54.1)
140 11 (4.8)
NOTE.—Among patients, the mean age SD was 34
 10.3 years; 125 (55%) were female, and 104 (44%)
were male. Patients were matched with healthy control
individuals, who had a mean age SD of 33.4 11.5
years (range 16–74 years) and included 43 females
(60.6%) and 28 males (39.4%).
ticipants gave informed consent before being included
in this study.
Sequencing
To identify common SNPs, PCR assays were designed
to cover the 12 exons of the CARD15 gene. The assays
were designed using Primer 3.0 software, which yielded
a target sequence of ∼700 bp that included a 100-bp
overlap with adjacent assays. The21M13 forward and
the 28 M13 reverse sequences were added to each of
the forward and reverse PCR primers, respectively. These
PCR primers were used to amplify 50 ng of genomicDNA
from eight independent individuals: six patients with CD,
one patient with ulcerative colitis, and one DNA sample
from CEPH that served as a control. We purified the PCR
products, using the solid-phase reversible immobilization
(SPRI) method (Hawkins et al. 1994), and sequenced
them, using the appropriate ABI PRISM BigDye Primer
21 M13 or M13REV Cycle Sequencing Kit (Applied
BioSystems). All sequencing reactions were run on ABI
377 automated sequencers (Applied BioSystems). The gel
files were subsequently processed using BASS software,
available on the Whitehead Institute/MIT Center for Ge-
nome Research FTP site. The forward and reverse reads
were then aligned to a GenBank reference sequence
(AC007728), using GAP4 software (Bonfield et al. 1998),
and all traces were visually inspected.
Genotyping of Arg702Trp, Gly908Arg, and
Leu1007fsinsC
DNA was extracted from peripheral blood lympho-
cytes, using a salting-out procedure (Miller et al. 1988).
Patients and control subjects were genotyped for the
Arg702Trp, Gly908Arg, and Leu1007fsinsC variants in
the CARD15 gene (GenBank accession number 64127),
as defined by Hugot et al. (2001). The missense mutation
Arg702Trp (also referred to as “Hugot SNP8”; GenBank
accession number G67950) was genotyped by amplifi-
cation refractory mutation system (ARMS) with primers
5′-ATCTGAGAAGGCCCTGCTCC-3′ (wild type, for-
ward), 5′-ATCTGAGAAGGCCCTGCTCT-3′ (mutated,
forward), and 5′-CCCACACTTAGCCTTGATG-3′ (re-
verse). ThemissensemutationGly908Arg (Hugot SNP12;
GenBank accession number G67951) creates a restriction
site for HhaI and was genotyped by an RFLP-PCR tech-
nique (5′-CCCAGCTCCTCCCTCTTC-3′ and 5′-AAGT-
CTGTAATGTAAAGCCAC-3′). The presence of a wild-
type allele results in an intact 380-bp band, whereas the
profile of the Gly908Arg variant is characterized by two
bands of 138 bp and 242 bp on 2% agarose gel. The
ARMS technique, as described by Ogura et al. (2001a),
was used to genotype the Leu1007fsinsC (SNP13; Gen-
Bank accession number G67955). The investigators who
performed the CARD15 genotyping were blinded with
respect to the clinical phenotype of each patient.
Genotyping 45 SNPs for CARD15 Haplotype Analyses
In a subgroup of 84 patients, we collected DNA from
both parents, and we genotyped the parent-offspring trios
with a dense set of SNPs. Specifically, the set included two
novel SNPs identified in the present study, 10 of the 13
SNPs reported by Hugot et al. (2001) (SNP1, SNP7, and
SNP9 were not examined), and an additional 33 SNPs
(rs1362390, rs746702, rs933568, rs1558663, rs745230,
rs749986, rs749985, rs1990624, rs752301, rs10193,
rs1420685, rs1981760, rs1362632, rs751271, rs748855,
rs1861758, rs1861757, rs1861756, rs749910, rs1077861,
rs718226, rs751919, rs1362698, rs1548990, rs1990752,
rs1477176, rs1420873, rs1548989, rs1420871,
rs1861762, rs2032688, rs2032687, and rs1861760) se-
lected from the UCSC Human Genome Project Working
Draft database. The SNPs were genotyped by time-of-
flight mass spectrometry (Ross et al. 1998), using the Se-
quenom platform. In brief, PCR primer pairs needed to
amplify the region around the SNP, as well as extension
primers, were designed using Sequenom SpectroDesigner
software. The PCR primers were used to amplify 5 ng of
genomic DNA in a multiplex reaction (as many as five
assays per reaction). Unincorporated nucleotides were re-
moved from the products of the PCR, using shrimp al-
kaline phosphatase treatment. The homogeneous mass
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extend reaction was then performed, adding one or two
bases to the extension primer, to include one variant of
the SNP or to include the alternate variant plus one base
beyond the SNP. The extension reaction was purified us-
ing Sequenom SpectroClean resin, and the purified prod-
ucts were placed on a 384-spot DNA chip. The chip was
run through a mass spectrometry workstation (Bruker),
and the resulting spectra were analyzed using the Se-
quenom Spectro TYPER-RT software.
Seven of the SNPs (rs752301, rs1420685, rs1362632,
rs751271, rs1548990, rs1990752, and rs1477176) from
the UCSC database did not genotype well (!75% of
the individuals were successfully genotyped), five of the
SNPs (rs10193, rs1362390, rs933568, rs1352598, and
rs1548989) were monomorphic or nearly so (0 or 1 copy
of the minor allele observed) in the 84 trios, and one SNP
(rs1861756) gave inaccurate genotyping results; hence,
these SNPs were removed from further analysis.
Haplotype Construction
Of the 32 well-genotyped, polymorphic SNPs, 7
(Arg702Trp, Gly908Arg, Leu1007fsinsC, rs746702,
rs2032688, rs2032687, and rs1861760) had minor al-
lele frequencies (MAF) !5%. Haplotype construction and
counting were performed with the remaining 25 poly-
morphic SNPs, as described elsewhere (Daly et al. 2001).
Specifically, haplotype percentages in figure 1 were com-
puted using haplotypes generated by the transmission/
disequilibrium test (TDT) implementation in GENE-
HUNTER 2.0 (Kruglyak et al. 1996), followed by the use
of an expectation-maximization algorithm, to include the
minority of chromosomes that had one or more mark-
ers with ambiguous phase (i.e., both parents and offspring
were heterozygous) or had one marker that was missing
genotype data. The SNPs with !5% MAF were then
added to the common haplotype patterns. Blocks are de-
fined as regions in which none of the common haplotypes
(13%) show evidence of recombination.
Statistics
Logistic regression (SPSS 10.0) was performed to as-
sess whether CARD15 mutations were correlated with
a particular clinical phenotype ( ). This analysisap .05
was performed on the group of patients (229/231) for
whom complete phenotype information was obtained.
Given the significant results of the correlation between
CARD15 genotypes and disease location, we specifically
examined (using Fisher exact test) whether the IBD5
haplotype also correlated to disease location.
The association between CARD15 genotypes and CD
was examined by combining the case-control data (147
cases and 71 controls) and the trio data (84 trios), which
was accomplished by calculating the observed and ex-
pected values and the variance of the number of mutant
alleles among cases and transmitted chromosomes, re-
spectively. These numbers were combined to create a stu-
dywide Z score for each mutation.
Results
Prevalence of CARD15 Sequence Variants in a Cohort
of Patients with CD from Quebec
To date, the prevalence of all three causal variants in
the CARD15 gene has only been reported for a European
population with CD (Hugot et al. 2001). We therefore
collected a cohort of 231 patients with CD from the Ca-
nadian province of Quebec and thoroughly character-
ized them for a number of demographic and clinical char-
acteristics (table 1). We then genotyped all patient and
healthy control samples for the three causal CARD15
variants and observed that the overall prevalence of
CARD15 mutations in the Quebec patients with CD
(45.0%; 103/229) was significantly higher than in healthy
control individuals (9.0%; 7/71) ( ). This obser-P ! .001
vation was true for all threemutationswhen patientswere
compared with control individuals (Arg702Trp: 12.9%
vs. 4.2%, ; Gly908Arg: 5.2% vs. 0.7%,Pp .004 Pp
; Leu3020fsinsC: 10.3% vs. 0.7%, ) (table 2)..02 P ! .001
No significant difference was seen in CARD15 variant
frequencies between patients with sporadic CD (only one
person affected in the family) (12.3%, 5.3%, and 11.7%
for Arg702Trp, Gly908Arg, and Leu3020fsinsC, respec-
tively) and patients with familial CD (minimum of two
persons affected in the family) (13.9%, 5.1%, and 7.7%,
respectively) (table 2). Of the 231 patients, 12 (5.2%)
were homozygotes for a particularmutant, and 15 (6.5%)
were compound heterozygotes. Given an overall fre-
quency of mutations in cases of 27.9%, an excess of pa-
tients with two mutations, when compared with the ex-
pectation (27 observed vs. 18 expected; ), confirmsP ! .05
previous reports of a significantly greater risk attributed
to double-mutant individuals. The estimated risk associ-
ated with carrying one or more CARD15 mutations is
odds ratio (95% CI 3.2–16.5).(OR)p 7.2
Genotype-Phenotype Correlation
Knowing the genotype status for the three CARD15
variants in a well-characterized, independent popula-
tion with CD, we can examine the genotype-phenotype
correlations in the disease process. We therefore per-
formed multivariate logistic regression and found that
disease localization is strongly correlated with the pres-
ence of the CARD15 variants. Specifically, patients
with ileal disease (either isolated ileitis or ileocolitis)
had a 2.3–2.9 increased risk of carrying CARD15 var-
iants, compared with patients with solely colonic in-
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Figure 1 Blocklike haplotype structure of the CARD15 gene. A, Common haplotype patterns in the four blocks of low diversity encom-
passing the CARD15 gene. Dashed lines indicate locations where 15% of all chromosomes were observed to connect one common haplotype
to another. Alleles at each SNP are indicated as numbers (1 p A, 2 p C, 3 p G, and 4 p T). All SNPs included in the haplotype structure
have an MAF 15%. The CARD15 gene (topmost purple box) represents the location of the gene in relation to the blocks. The gray vertical
bars represent intervals of historical recombination between the blocks. Distances between Blocks 1 and 2, 2 and 3, and 3 and 4 are 33 kb,
14 kb, and 3 kb, respectively. B, Percentage of each of the common patterns among all observed chromosomes (transmitted and untransmitted).
C, Haplotype structure of the wild-type haplotype C (Cwt), which contains no risk alleles, and the three subvariants of haplotype C (C1, C2,
C3), which confer risk of CD. For the three subvariants, blocks 2, 3, and 4 are in tight LD; therefore, all three blocks are displayed. Greater
recombination is seen between blocks 2, 3, and 4 for the wild-type haplotype C, so only block 3 is displayed. SNPs that confer risk of CD are
highlighted in red and boxed. D, Frequencies and transmitted:untransmitted ratios of the specified allele calculated for each individual SNP.
The SNPs that confer risk of CD are highlighted in red and boxed. E,Overall frequencies and frequency among transmitted (FT) and untransmitted
(FU) chromosomes for the common block 3 haplotypes (A, B, and C [top]) and for the Cwt and C subvariant block 3 haplotypes (C1, C2, and
C3) (bottom).
volvement ( ) (table 3). No other demographicP ! .001
or clinical variables were associated with the presence
or absence of the CARD15 variants, in a multivariate
model.
Given the significant results of the correlation between
CARD15 genotypes and disease localization, we were
interested to knowwhether the IBD5 haplotypewas also
correlated with disease localization. Examination of the
84 CD trios, however, revealed no correlation between
IBD5 genotypes and disease localization. Furthermore,
we found that 74% of all CARD15-positive cases had
at least one copy of the IBD5 risk haplotype, which was
not significantly different from the frequency (76%) in
the total population of cases. Finally, stratification of the
data on the basis of CARD15 or IBD5 genotypes re-
vealed no interaction between these two loci.
Analysis of the Genetic Variation Surrounding the
CARD15 Gene
To identify common SNPs in the CARD15 gene, the
gene was resequenced in DNA samples obtained from
six patients with CD, one patient with ulcerative co-
litis, and one control individual. Specifically, we re-
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Table 2
Allele Frequencies for Arg702Trp, Gly908Arg, and Leu1007fsinsC in the Study
Population
MUTATION
FREQUENCY IN
Pa
Patients
with CD
(np 231)
Patients with
Sporadic IBD
(n p 135)
Patients with
Familial IBD
(n p 96)
Control
Individuals
(n p 71)
Arg702Trp 12.9 12.3 13.9 4.2 .0012
Gly908Arg 5.2 5.3 5.1 .7 .0022
Leu1007fsinsC 10.3 11.7 7.7 .7 5.6 # 10–8
Overall 45.0 45.3 44.3 9.0 2.9 # 10–8
NOTE.—P values were computed by combining the results of the comparison of 147
patients and 71 control subjects with the TDT results from the remaining 84 patients who
had both parents genotyped, as described in “Subjects and Methods.” No significant dif-
ferences were found between patients with sporadic and familial disease.
a Patients with CD vs. control subjects.
sequenced all coding regions, all intron-exon bound-
aries, and both UTRs. This resulted in the identifi-
cation of two novel SNPs: one in the 5′ UTR in exon
1 (59 bp from start codon GTAGACAGATCCAG-
GCTCACCAGTCCTGTGCCACTGGGCTTTTGGC-
[G/A]TTCTGCACAAGGCCTACCCGCAGATGCC-
ATGCCTGCTCCCCCAGCC) and one in the 3′ UTR
in exon 12 (4,279 from start codon TGTTATTATT-
TTAAACATTATGATGTGTGAAAACTGGTTAAT-
ATTTATAG[A/G]TCACTTTGTTTTACTGTCT-
TAAGTTTATACTCTTATAGACAACATGGCC-
GTG).
These two novel SNPs, as well as 10 SNPs reported by
Hugot et al. (2001) and 33 SNPs selected from the UCSC
Human Genome Working Draft database, were geno-
typed in the 84 CD trios. Thirty-two of the 45 SNPs were
polymorphic in this group and were successfully typed in
at least 93% of all samples. These 32 SNPs span a ge-
nomic region of 177 kb, encompassing the entire geno-
mic extent (36 kb) of the CARD15 gene, as well as a
68.3-kb and a 72.7-kb region that flank this gene (to the
left and right, respectively). Using the TDT, we examined
the CARD15 mutations (Arg702Trp, Gly908Arg, and
Leu1007fsinsC) reported by Hugot et al. (2001) for as-
sociation with CD. All three were overtransmitted from
parents to affected children. Specifically, the transmit-
ted:untransmitted (T:U) ratios for these three variants
were 1.8:1 (Arg702Trp), 3.0:1 (Gly908Arg), and 12.0:
1 (Leu1007fsinsC) (see fig. 1D). These results were com-
bined with the case-control data by calculating a Z score.
This demonstrated that all three variants were signifi-
cantly associated with CD in this Quebec population:
Arg702Trp ( ; ), Gly908Arg (Zp 3.05 Pp .0012 Zp
; ), and Leu1007fsinsC ( ;2.85 Pp .0022 Zp 5.31 Pp
). Examination of the remaining common85.6# 10
SNPs in the 84 CD trios by TDT analysis revealed five
additional SNPs with T:U ratios 1.8, resulting from
linkage disequilibrium (LD) with the three reported mu-
tations. Importantly, public SNP rs749910 (located be-
tween Gly908Arg and Leu1007fsinsC) is one of the SNPs
associated with CD, suggesting that publicly available
SNPs were adequate to detect CARD15 involvement in
disease susceptibility.
Because recent work by our group and others has in-
dicated that the genetic variation in the human genome
has a discrete haplotype block structure (Jeffreys et al.
2000; Daly et al. 2001), we sought to identify the pattern
of common variation surrounding the CARD15 gene.
This was achieved by examining the 25 SNPs that had
MAF 15%. We observed that the entire 177-kb region
could be parsed into four discrete blocks (each spanning
14–70 kb [fig. 1A] and having two to four common an-
cestral haplotypes) that account for 91% of all chro-
mosomes. Among these common haplotypes, no evidence
exists of recombination within each block. Block 3 con-
tains most, if not all, of the coding sequence of the
CARD15 gene, and the genetic variation in this block
falls into three common haplotype patterns (labeled in fig.
1A as “Haplo A,” “Haplo B,” and “Haplo C”). Exam-
ination of the T:U ratio in this block indicates that the
“C” haplotype is overtransmitted fromparents to affected
offspring (T:Up 1.6–1.8:1), whereas the other two hap-
lotypes are undertransmitted (fig. 1D and 1E).
The inclusion of the three CARD15 causal variants
in this analysis demonstrates that, intriguingly, the dis-
ease alleles are all located on the “C” haplotype and
create three subvariants (labeled “C1,” “C2,” and “C3”;
fig. 1C). All three subvariant haplotypes are overtrans-
mitted from parents to affected offspring, whereas the
wild-type C haplotype that carries the nonrisk alleles for
these three variants is undertransmitted. Examination of
the longer-range haplotype patterns on chromosomes
carrying the CARD15 risk alleles demonstrates that the
C1, C2, and C3 subhaplotypes exist as different combi-
nations of block 3 with its adjacent haplotype blocks.
These data strongly support the theory that the three
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Table 3
Relationship between CARD15 Variants and Disease Phenotypes
CHARACTERISTIC CARD15a CARD15a
UNIVARIATE ANALYSIS MULTIVARIATE ANALYSIS
OR 95% CI OR 95% CI
Mean age (years) 34.6 33.6 .991 .966–1.017 .989 .962–1.018
Female/male 56.0/44.0 52.4/47.6 1.155 .684–1.950 1.040 .593–1.826
Smoking 26.5 25.3 .936 .494–1.774 … …
Localization:
Ileitis 26.0 34.0 2.812 1.403–5.639 2.277 1.064–4.871
Colitis 43.9 20.4 1.00 … 1.00 …
Ileocolitis 30.1 45.6 3.266 1.683–6.339 2.858 1.412–5.785
Behavior:
Inflammatory 52.5 43.7 1.00 … 1.00 …
Stricturing 14.7 22.3 1.817 .880–3.753 1.150 .498–2.660
Fistulizing 32.8 34.0 1.244 .688–2.251 .857 .416–1.767
Surgery 44.0 58.0 1.776 1.048–3.009 1.478 .758–2.880
Extraintestinal manifestations 41.6 40.8 .967 .567–1.642 .990 .556–1.764
Familial IBD 34.4 34.0 .982 .556–1.701 .875 .487–1.571
Age at diagnosis (years):
!20 39.5 42.7 1.00 … 1.00 …
20–40 57.3 50.5 .816 .474–1.402 1.135 .608–2.120
140 3.2 6.8 1.949 .534–7.109 4.940 .964–25.324
a Data are percentages, except as otherwise noted.
risk alleles arose independently on different chromo-
somes that, coincidentally, were locally identical.
Discussion
A susceptibility locus for CD on the pericentromeric re-
gion of chromosome 16 was initially described by Hugot
et al. (1996); since then, the gene underlying the IBD1
locus has been identified as CARD15 (Hugot et al. 2001;
Ogura et al. 2001a). The identification of the first gene
that confers susceptibility to CD is a pivotal step toward
an understanding of the causation of this debilitating dis-
ease. Specifically, the report by Hugot et al. identifying
three CARD15 sequence variants conferring susceptibil-
ity to CD (Hugot et al. 2001), the independent identifi-
cation by Ogura et al. (2001a) of one of these variants
(Leu3020insC), and the confirmation of this same variant
in an independent European cohort (Hampe et al. 2001)
provide an opportunity to ask specific questions regarding
the role of this gene in disease susceptibility. The questions
include the following: (1)What is the contribution of these
variants in geographically diverse patient populations? (2)
What is the spectrum of risk-conferring alleles for this
gene? (3) How does the presence of these alleles influence
the clinical phenotype? (4) How do these variants interact
with other susceptibility loci? (5) By what specific mech-
anism(s) do these variants confer disease susceptibility?
In an attempt to answer some of these important
questions, we collected a cohort of 231 patients with
CD from the Canadian province of Quebec, and we
conducted rigorous clinical phenotyping of all patients,
including verification of diagnosis according to well-
defined criteria (Gasche et al. 2000). We found that the
prevalence of CARD15 mutations in the Quebec pa-
tients with CD (Arg702Trp, 12.9%; Gly908Arg, 5.2%;
and Leu1007fsinsC, 10.3%) was very similar to what
was reported by Hugot et al. (2001). The prevalences
of homozygotes (5.2%) and compound heterozygotes
(6.5%) observed in the present study were also similar
to those reported by Hugot et al. (2001) (6.0% and
8.5%, respectively). Taken together, these data identify
a significant association of all three CARD15 sequence
variants with CD.
To study the genetic variation surrounding the
CARD15 gene, we performed SNP discovery in a lim-
ited number of individuals and genotyped a subset of
our cases (those for whom we had parental DNA) for
45 sequence variants identified in the present study, the
study by Hugot et al., and the public SNP database.
The specific aim was to determine the haplotype struc-
ture of this genomic region, to determine the extent of
LD, and to address the question of whether other com-
mon variants exist that could explain the association of
CARD15 with CD.
Recent attempts to characterize the haplotype struc-
ture of specific genomic regions have indicated that the
genetic variation in humans largely follows simple pat-
terns (Jeffreys et al. 2000; Daly et al. 2001; Patil et al.
2001). This pattern of common variation has been de-
scribed as blocklike, because regions exist in which there
is little or no evidence of recombination and because
intervals between these regions show evidence of mul-
tiple historical recombination events. The variation be-
tween individual chromosomes is therefore a result of
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the specific combinations of the limited number of hap-
lotypes that exist in each block. This pattern suggests
that examination of the haplotype-block structure sur-
rounding a gene allows for a comprehensive analysis of
the association of the gene with disease, even if the
causal variants have not been identified (Daly et al.
2001; Goldstein et al. 2001).
We therefore examined the haplotype structure for a
177-kb region that encompassed the entire 36-kb
CARD15 gene. We demonstrated that this region can be
parsed into discrete haplotype blocks, with a limited
number of common haplotypes per block, as the study
of the other genomic regions suggested. Importantly, we
observed that the use of common SNPs could identify a
haplotype (haplotype C) that had evidence of associ-
ation with CD (fig. 1). When the three causal alleles
were added to the analysis, it was observed that all were
unique to the C haplotype, thus creating three indepen-
dent subvariants of this haplotype, which is consistent
with the initial observation made in a European popu-
lation (Hugot et al. 2001). Moreover, these three variants
are uniquely found on chromosomes with two different
mosaic patterns of blocks 2, 3, and 4. This observation
is consistent with these variants having arisen on indi-
vidual chromosomes that had previously undergone re-
combination between the ancestral haplotypes, and it in-
dicates a more recent history for these variants. The
observation that the Cwt haplotype (i.e., the C haplotype
without any of the three causal variants) is not associated
with CD, together with our knowledge of the block struc-
ture of this region, strongly suggests that there are no
additional common causal variants to be identified on
the A, B, or Cwt haplotypes. However, the work of Hugot
et al. (2001) suggests the existence of some rare variants
in CARD15 that contribute to disease risk.
Although grouped under the same unifying term, pa-
tients with CD clinically present with heterogeneous dis-
ease characteristics, including large differences in dis-
ease behavior, localization, and severity. Defining the
relationship between CARD15 variants and phenotyp-
ic variation in disease presentation is not only central
to probing the clinical diversity in disease presentation
and behavior but may also assist in defining rational
treatment strategies. In the present study we found a
significant association between ileal disease localiza-
tion and CARD15 variants. This finding is consistent
with the recent report by Lesage et al. (2002), which
associated CARD15 variants with less frequent colonic
involvement.
In addition, some studies have suggested that familial
and sporadic IBD are two distinct entities, because of the
differences in disease localization and behavior between
the two groups (Peeters et al. 2000). The CARD15 var-
iants have thus far primarily been examined in multiply
affected families. In the present study, however, we were
able to examine the frequency of CARD15 variants in
both familial and nonfamilial cases, and we observed
no differences, regardless of familial disease history (ta-
ble 2).
We recently reported that genetic variation in the cy-
tokine gene cluster on chromosome 5q31 confers risk of
CD (Rioux et al. 2001). This IBD5 risk haplotype is
found in ∼75% of patients with CD examined in a num-
ber of independent patient collections from the Cana-
dian provinces of Ontario and Quebec, including the
group of trios examined in the present study. Having the
CARD15 and IBD5 variants genotyped in the same pop-
ulation allows for the examination of potential locus-
locus interactions. In the present study there was no ev-
idence of these two loci interacting, which is consistent
with the preliminary observation that we made in sam-
ples from Ontario (Rioux et al. 2001). It is nevertheless
possible that the number of trios studied did not have
sufficient power to detect such an interaction and that
larger cohorts of trios will be necessary to further char-
acterize any possible interactions.
The underlying mechanism by which CARD15 vari-
ants confer susceptibility to CD remains incompletely
understood. Initial work by Ogura et al. (2001a) on the
Leu1007fsinsC variant suggests that this susceptibility
potentially relates to a deficit in the ability to sense bac-
teria in the gastrointestinal environment. A deficit in sens-
ing bacteria would then result in an exaggerated inflam-
matory response of the adaptive immune system. Our
observation that these sequence variants are associated
with ileal disease may provide additional clues to the
mechanisms of disease. Although the idea that there are
differences in the bacterial ecosystem between the colon
and the ileum is speculative, such differences could cer-
tainly account for differences in disease presentation
(Shanahan 2002). It is possible that the beneficial effect
of antibiotics, seen predominantly in patients who have
CDwith isolated colonic involvement, reflects a subgroup
of patients who have gastrointestinal systems that are
more efficient in recognizing and subsequently defending
against bacterial invasion than are those in patients with
primarily ileal disease (Greenbloom et al. 1998). How-
ever, well-designed trials would be necessary to prove this
hypothesis.
In conclusion, the results of our study confirm that
three sequence variants in the CARD15 gene confer risk
of CD. Haplotype analysis also suggests that these var-
iants are likely to have arisen recently on individual
chromosomes that originate from a common ancestral
haplotype. Finally, our observation that these sequence
variants are correlated with a specific disease subphe-
notype is another step toward understanding how se-
quence variation in CARD15 influences disease suscep-
tibility in CD.
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